Recursion Pharmaceuticals (RXRX) Projected to Post Quarterly Earnings on Monday

Key Points

• Upcoming Q1 2026 results: Recursion is set to report before the market opens on Monday, May 4 at 8:00 AM ET, with analysts expecting a (‑$0.27) EPS and about $17.46 million in revenue.
• In the prior quarter the company beat EPS estimates (reported (‑$0.21) vs. consensus (‑$0.28)) and revenue jumped 671.7% year‑over‑year to $35.54 million, but it remains deeply unprofitable with a negative net margin of 863% and analysts forecast roughly (‑$1) EPS for the current and next fiscal year.
• Insiders have sold shares recently while institutional ownership is high at 89.06%, and analyst sentiment is mixed with a consensus Hold and an average target price of $9.40.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) is anticipated to issue its Q1 2026 results before the market opens on Monday, May 4th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $17.46 million for the quarter. Parties may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 4, 2026 at 8:00 AM ET.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.07. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on equity of 63.98%. The business had revenue of $35.54 million for the quarter, compared to analysts' expectations of $24.56 million. During the same period in the previous year, the company posted ($0.53) EPS. Recursion Pharmaceuticals's revenue was up 671.7% on a year-over-year basis. On average, analysts expect Recursion Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Recursion Pharmaceuticals Stock Performance

Recursion Pharmaceuticals stock opened at $3.51 on Monday. The company's fifty day simple moving average is $3.41 and its 200-day simple moving average is $4.24. The company has a quick ratio of 5.50, a current ratio of 5.50 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals has a 12 month low of $2.80 and a 12 month high of $7.18. The stock has a market cap of $1.85 billion, a P/E ratio of -2.37 and a beta of 1.02.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CFO Ben R. Taylor sold 7,956 shares of the company's stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $3.39, for a total transaction of $26,970.84. Following the completion of the sale, the chief financial officer directly owned 1,180,318 shares in the company, valued at $4,001,278.02. This represents a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Blake Borgeson sold 30,000 shares of the company's stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $3.10, for a total transaction of $93,000.00. Following the sale, the director owned 6,229,863 shares of the company's stock, valued at $19,312,575.30. This trade represents a 0.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 299,680 shares of company stock worth $1,180,121 over the last ninety days. Company insiders own 8.43% of the company's stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of hedge funds have recently bought and sold shares of RXRX. Brighton Jones LLC boosted its holdings in Recursion Pharmaceuticals by 49.4% during the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company's stock valued at $137,000 after acquiring an additional 6,699 shares during the period. Royal Bank of Canada boosted its holdings in Recursion Pharmaceuticals by 627.6% during the first quarter. Royal Bank of Canada now owns 269,013 shares of the company's stock valued at $1,423,000 after acquiring an additional 232,038 shares during the period. AQR Capital Management LLC bought a new stake in Recursion Pharmaceuticals during the first quarter valued at about $890,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Recursion Pharmaceuticals by 7.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company's stock valued at $953,000 after acquiring an additional 12,372 shares during the period. Finally, Focus Partners Wealth bought a new stake in Recursion Pharmaceuticals during the first quarter valued at about $77,000. 89.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

RXRX has been the topic of several research analyst reports. Wall Street Zen cut shares of Recursion Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, March 28th. Weiss Ratings restated a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a report on Tuesday, April 21st. Bank of America lowered their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "neutral" rating on the stock in a report on Wednesday, February 25th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, February 26th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Recursion Pharmaceuticals has a consensus rating of "Hold" and an average target price of $9.40.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc NASDAQ: RXRX is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.